💰 Gene therapy supplier MIP Discovery has raised £7M in Series A financing to support the commercialization of its synthetic affinity reagents in cell and gene therapy. The funding was led by Mercia Ventures and also included Calculus Capital and angel investors. MIP Discovery develops synthetic antibodies called Molecularly Imprinted Polymers (nanoMIPs), which have high affinity and specific binding sites and can be used in viral vector characterization and purification. The funds will be used for commercialization and hiring staff.
📢 Revolutionary Gene Therapy Supplier Raises £7M
Introduction:
British gene therapy vector specialist MIP Discovery Ltd has closed a £7M Series A financing round. The funding will be used to drive the commercialization of the company’s synthetic affinity reagents in cell and gene therapy.
Main points:
- The £7M Series A financing was led by Mercia Ventures, with participation from existing investor Calculus Capital and angel investors.
- MIP Discovery will use the funding to further commercialize its synthetic affinity reagents and to hire new staff.
- The company’s non-biological affinity reagents offer a new approach to viral vector characterization, purification, and safety and QC processes.
- MIP Discovery develops Molecularly Imprinted Polymers (synthetic antibodies) that have a high affinity and specificity binding site.
- These synthetic affinity reagents provide an advanced alternative to biologicals for downstream processing in cell and gene therapy development.
Conclusion:
The £7M Series A financing secured by MIP Discovery will enable the company to accelerate the commercialization of its synthetic affinity reagents in cell and gene therapy. These reagents offer a new approach to viral vector characterization and purification, as well as safety and QC processes. With the potential to replace traditional biologicals, these synthetic affinity reagents have the potential to greatly improve downstream processing in the development of cell and gene therapies.
